Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;39(8):2035-2038.
doi: 10.1038/s41375-025-02658-8. Epub 2025 Jul 12.

Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma

Shi-Hua Zhao #  1 , Zun-Min Zhu #  2 , Tao Yang #  3 , Da Gao #  4 , Li-Hong Liu  5 , Wei Yang  6 , Xiao-Bo Wang  7 , Yu-Xia Zhao  8 , Meng Li  1 , Yi-Nan Gao  9 , Rong-Jun Ma  2 , Ying Yang  6 , Hui-Ping Li  4 , Li Li  7 , Xiao-Lei Ao  8 , Xiu-Bin Xiao  1 , Chong-Ling Hu  3 , Shun-Zong Yuan  1 , Yao Ding  3 , Xi-Lin Chen  1 , Jian-Xia He  10 , Yao Liu  11 , Wen-Rong Huang  12
Affiliations

Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma

Shi-Hua Zhao et al. Leukemia. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: This study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local laws; and was approved by the ethics committee of participating centers. All patients provided written informed consent for participation.

Figures

Fig. 1
Fig. 1. Tumor response and survival.
A Swimmer-plot showing the clinical course and outcome events of each patient. B Evolution over treatment cycles of the response to induction therapy. C Kaplan-Meier plot for the duration of response. D Kaplan-Meier plots for progression-free survival. E Kaplan-Meier plots for overall survival. GCB germinal center B-cell-like, ECOG PS Eastern Cooperative Oncology Group performance status, CR complete response, PR partial response, SD stable disease, PD progressive disease.
See this image and copyright information in PMC

References

    1. Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:565–77. - PMC - PubMed
    1. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–227. - PubMed
    1. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017;31:833–43.e835. - PMC - PubMed
    1. Gao Y, Ping L, Shan C, Huang H, Li Z, Zhou H, et al. High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study. Blood Cancer Discov. 2025;6:191–202. - PMC - PubMed
    1. Grommes C, Younes A. Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis. Cancer Cell. 2017;31:731–3. - PMC - PubMed

LinkOut - more resources